Indeed, there is a CD276 targeting CAR T-cell immunotherapy phase I clinical trial investigation (BrainChild-03) in pediatric CNS tumors open and currently recruiting (NCT04185038) (21). Here, CD276 is linked to central nervous system neoplasm.